Shares of Tylenol maker Kenvue (KVUE) moved lower after the Wall Street Journal reported, citing people familiar with the matter, that Health Secretary Robert F. Kennedy Jr. plans to link pregnant women’s use of the pain killer to autism. The report is expected this month and will lhighlight that low-levels of folate and Tylenol taken during pregnancy could cause autism, sources told the Journal. Shares of Kenvue are down 7% to $19.10 following the report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Kenvue Inc put volume heavy and directionally bearish
- Third Point boosts position in Nvidia, takes new stakes in Mr Cooper, Meta
- Jeffrey Smith’s Starboard Value buys TripAdvisor in Q2
- Kenvue, Inc. Faces Uncertainty Amid Strategic Review: Potential Risks and Impacts on Future Performance
- Kenvue price target lowered to $26 from $29 at Canaccord